ABSTRACT
Objectives In this study, a comparative study between primers from Japan’s and US’s disease control centers was conducted. As further investigation, virus sequence alignment with primers’ oligonucleotide was analyzed.
Design or methods 11,652 samples from Japanese population were tested for SARS-CoV-2 positive using recommended RT-PCR primer-probe sets from Japan National Institute of Infectious Disease (NIID) and US Centers for Disease Control and Prevention (CDC).
Results Of the 102 positive samples, 17 samples (16.7% of total positives) showed inconsistent results when tested simultaneously for the following primers: JPN-N2, JPN-N1, CDC-N1, and CDC-N2. As a result, CDC recommended primer-probe sets showed relatively higher sensitivity and accuracy. Further virus sequence alignment analysis showed evidences for virus mutation happening at primer’s binding sites.
Conclusions The inconsistency in the RT-PCR results for JPN-N1, JPN-N2, CDC-N1, and CDC-N2 primer-probe sets could be attributed to differences in virus mutation at primers’ binding site as observed in sequence analysis. The use of JPN-N2 combined with CDC-N2 primer produces the most effective result to reduce false negatives in Japan region. In addition, adding CDC-N1 will also help to detect false negatives.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.niid.go.jp/niid/images/epi/corona/2019-nCoVmanual20200217-en.pdf
Funding Statement
This work is supported by Genesis Healthcare Corporation. The sponsor has no influence in the study other than providing resources and facility in conducting research and publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Biological samples were collected from volunteers, self-medication testing participants and patients under physician care administering clinical testing for SARS-CoV-2 (COVID-19). Samples were anonymized and de-identified, so laboratory technicians and researchers were blind to the identity of the patients. Only secondary non-identifying data including age, biological sex and symptoms were provided. All experimental protocols were approved by Genesis Healthcare's Ethics Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used and produced in this research are available at: https://github.com/genesis-healthcare/covid-19_pcr_irregularities
